Amylyx Pharmaceuticals, Inc.
AMLX · XNASCIK 1658551fmd_1SJ39ZAE8563MFEAY4KD3QK2V8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 0 | 22 | 381 | 87 | 0 |
| Cost of revenue | – | 3 | 25 | 6 | 0 |
| Gross profit | – | 19 | 355 | 81 | 0 |
| Research and development | 44 | 93 | 128 | 104 | 90 |
| Selling, general and administrative | 39 | 127 | 188 | 114 | 63 |
| Operating income | (83) | (201) | 39 | (315) | (153) |
| Interest and investment income | 0 | 4 | 16 | 14 | 9 |
| Other non-operating income (expense) | (5) | 4 | 15 | 13 | 9 |
| Income before taxes | (88) | (198) | 54 | (302) | (145) |
| Income tax expense | – | 1 | 5 | (0) | 0 |
| Net income from continuing operations | – | (198) | 49 | (302) | (145) |
| Net income | (88) | (198) | 49 | (302) | (145) |